Immediate-release niacin (vitamin B3)
Niacin (Immediate-Release Nicotinic Acid) · also known as Niacin, Immediate-release niacin, Nicotinic Acid, Flush niacin
Immediate-release niacin is a confirmed NAD+ precursor in humans. At pharmacologic doses it can raise HDL-C, but it often causes skin flushing. The eNOS- and AMPK-related mechanisms have not been confirmed in humans.
Clinical uses and human evidence
High LDL cholesterol
Studies (2)
- Knopp 1998 · Metabolism · RCT · n=223 — Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia
- McKenney 1994 · JAMA · RCT · n=46 — A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients
High triglycerides
All-cause mortality risk
Heart attack, stroke and other cardiovascular events
Studies (2)
- D'Andrea 2019 · JAMA Netw Open · Meta-analysis · n=35760 — Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
- Schandelmaier 2017 · Cochrane Database Syst Rev · Meta-analysis · n=39195 — Niacin for primary and secondary prevention of cardiovascular events
Mechanisms of action
Replenishing the NAD+ pool via the salvage pathway
Niacin is converted via the Preiss–Handler pathway, catalyzed by NAPRT, into nicotinic acid mononucleotide, which is then used to synthesize NAD+. This is a known synthesis route in humans. Human studies have confirmed that niacin is a precursor of NAD+, but the size of the rise depends on dose, tissue and nutritional status.
Endothelial nitric oxide synthase (eNOS) coupling and NO vasodilation
The skin flushing from niacin comes from prostaglandin release after GPR109A receptor activation, not from eNOS activation. Vascular effects linked to eNOS have been seen in specific animal models, such as diabetic ischemia, but they cannot be extrapolated to a vasodilating effect at usual doses in humans.
AMPK sensing of cellular energy deficit and metabolic reprogramming
Some studies suggest niacin reduces hepatic triglyceride synthesis and VLDL secretion, but this is not the same as AMPK activation. In the livers of mice on a high-fat diet, niacin can indirectly increase AMPK phosphorylation, but there is no direct evidence in humans.
Safety and drug interactions
Added liver burden
High doses, especially extended-release forms, are hepatotoxic. Each of these has case reports of liver injury. If several are taken together long term, have liver function checked regularly. Stop them right away and see a doctor if you develop fatigue, poor appetite, yellowing of the skin or whites of the eyes, or darker urine.
With Antidiabetic drugs Needs attention
High-dose niacin raises blood sugar and may weaken the effect of antidiabetic drugs.
With Statins Needs attention
Combining high-dose niacin with a statin increases the risk of muscle injury. Seek prompt medical attention for muscle aches or weakness. The U.S. prescribing information specifically states that, in Chinese patients taking simvastatin, combining it with more than 1 g/day of niacin is not recommended.
Related lab tests
Fasting glucose and hemoglobin A1c Recheck while taking
High-dose niacin raises blood glucose. People with diabetes or prediabetes should recheck blood glucose about 2 months after starting.
Lipid panel Recheck while taking
When niacin is used under medical supervision to adjust blood lipids, recheck the lipid panel to see the effect.
Uric acid Recheck while taking
Niacin raises uric acid and may trigger gout. Test once before starting, recheck during dose increases, and then about every 6 months.
Liver function tests Recheck while taking
Niacin may cause liver injury. Test once before starting, then recheck regularly during dose increases and afterward, roughly every 2 months.